1.1 Basic R&D & Chemical Profile
Odanacatib, internal research code MK-0822, is an oral small-molecule cysteine protease inhibitor originally co-developed by Merck & Co. and a biotech licensing partner. Its CAS registry number is 603139-19-1, formulated as oral tablets for once-weekly oral administration; tablets must be swallowed whole without splitting, crushing or chewing. No proprietary brand naming is adopted in clinical and chemical research documents.
1.2 Mechanism of Action
The compound delivers potent, selective reversible inhibition against cathepsin K, a lysosomal protease highly expressed in osteoclasts. Cathepsin K acts as the primary enzyme that breaks down collagen in bone matrix to drive bone resorption.
It binds tightly to the active catalytic pocket of cathepsin K with subnanomolar inhibitory potency (IC ₅₀ = 0.2 nM for human cathepsin K), while showing minimal binding affinity to other cathepsin subtypes including B, L and S, which limits off-target interference with non-bone tissues.
Pharmacological effects: Suppress excessive bone resorption markers by 60%–70%; bone formation activity is only mildly reduced rather than fully blocked, enabling steady elevation of bone mineral density without drastic suppression of bone remodeling cycles.
1.3 Pharmacokinetic Characteristics
Absorption: Plasma peak concentration appears 2–6 hours after oral intake. Absolute bioavailability differs by dose strength: 70% for 30 mg doses and 30% for 50 mg doses. Co-administration with high-fat meals elevates bioavailability to 49% for 50 mg tablets and delays peak concentration to around 10.5 hours.
Distribution: Steady-state volume of distribution reaches 100 L; approximately 97.5% of circulating compound binds to plasma proteins.
Metabolism & excretion: Hepatic metabolic clearance dominates elimination. Around 74.5% of metabolic waste discharges via feces, and only 16.9% exits through urine, creating low renal burden. Long plasma half-life supports a once-weekly oral dosing regimen.
1.4 Investigational Indications & Clinical Efficacy
The core investigational indication was osteoporosis management for postmenopausal women with low bone mineral density and elevated fracture risk. Large-scale Phase 3 trials (the LOFT trial program) enrolled over 16,700 elderly postmenopausal female participants across global clinical sites:
Continuous 5-year oral intake significantly increased lumbar spine and hip bone mineral density, improved bone microarchitecture, and lowered risk of vertebral, hip and nonvertebral fragility fractures versus placebo groups.
Secondary exploratory indications included skeletal disorders linked to abnormal bone turnover and bone metastasis-related bone loss.
1.5 Safety Profile & Development Termination
General mild adverse responses reported in early trials included headache, transient flu-like malaise and throat discomfort. No jaw osteonecrosis signals were observed during long-term observation, while rare atypical subtrochanteric fractures and localized skin lesions were documented in a small number of subjects.
Critical cardiovascular risk findings emerged from extended Phase 3 follow-up: participants receiving weekly odanacatib demonstrated statistically higher incidence of stroke and composite major adverse cardiovascular events compared to placebo cohorts. Due to unfavorable risk-benefit balance, the sponsor terminated all further clinical development and regulatory filing plans for this molecule.
2. Full Introduction to Orforglipron (Code LY3502970)
2.1 Basic R&D & Chemical Profile
Orforglipron is a first-in-class orally active non-peptide small-molecule GLP-1 receptor agonist. The molecular scaffold was first synthesized and screened by Chugai Pharmaceutical Co., Ltd., and Eli Lilly obtained exclusive global development, clinical trial and commercialization rights in 2018. Its chemical entity is orforglipron calcium salt with CAS No. 2212020-52-3, produced as film-coated oral tablets for once-daily oral intake. Tablets require intact swallowing and cannot be split, crushed or chewed. No commercial brand names are referenced in this introduction.
2.2 Unique Mechanism of Action
Distinct from peptide-based GLP-1 compounds that bind the extracellular domain of GLP-1 receptors, orforglipron targets an allosteric transmembrane pocket of the GLP-1 receptor. This structural design confers robust gastrointestinal stability against protease degradation, removing the requirement for absorption boosters used by alternative oral GLP-1 candidates. Three core metabolic pathways are modulated:
Glucose-dependent insulin release: Activate pancreatic β-cells to secrete insulin only under elevated blood glucose levels, while restraining excessive glucagon output from α-cells to cut hepatic glucose production; hypoglycemia risk remains minimal during monotherapy.
Central appetite modulation: The small molecule crosses the blood-brain barrier to regulate hypothalamic feeding circuits, reducing subjective hunger and extending post-meal satiety. It also moderately slows gastric emptying to prolong fullness sensations.
Balanced receptor signaling: It functions as a partial GLP-1 agonist that preferentially activates the cAMP/PKA signaling cascade with low β-arrestin recruitment, leading to milder gastrointestinal adverse reactions compared with peptide GLP-1 therapeutic agents.
2.3 Pharmacokinetic Advantages
Flexible dosing rules: Once-daily administration with no mandatory fasting requirements. Tablets can be consumed at any time point throughout the day alongside meals, beverages or snacks with no restrictions on pre/post-dose food or water volume, substantially improving long-term treatment adherence versus competing oral GLP-1 options.
Absorption and elimination: Plasma peak concentration occurs 1–2 hours after oral dosing. Over 99% of circulating compound binds to plasma proteins. Primary metabolic clearance relies on hepatic CYP3A4 enzymes, with an elimination half-life of 30–40 hours to sustain once-daily dosing. More than 80% of metabolites are eliminated via feces with limited renal excretion load.
Standard dose titration protocol to minimize adverse effects: 0.8 mg daily for a minimum of 30 days → 2.5 mg daily for a minimum of 30 days → 5.5 mg daily. Maintenance therapeutic strengths include 6 mg, 12 mg and 36 mg daily; no more than one tablet may be taken within any 24-hour period.
2.4 Approved & Investigational Indications
Approved Indication (U.S. FDA, April 2026)
Orforglipron is indicated for adult patients living with obesity, or overweight individuals accompanied by at least one weight-related comorbidity such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. Treatment must be combined with reduced-calorie dietary plans and consistent physical activity to decrease excess body mass and maintain long-term weight control. Concurrent use with any other GLP-1 receptor agonist is not recommended.
Ongoing Phase 3 Clinical Development Programs
Type 2 diabetes mellitus: The ACHIEVE Phase 3 trial series evaluates glycemic control, body weight reduction and cardiovascular safety in diabetic populations. Head-to-head trials against oral semaglutide verified superior HbA1c lowering and weight loss efficacy under matched treatment durations.
Secondary metabolic targets: Active clinical trials are underway to assess efficacy for obstructive sleep apnea, hypertension, knee osteoarthritis pain, peripheral artery disease and stress urinary incontinence in overweight and obese adult populations.
United States
